Eli Lilly | LLY - Cash And Equivalent


Eli Lilly reported $7.27B in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
AbbVie USD 5.23B 400M Dec/2025
Abbott USD 8.52B 1.01B Dec/2025
ALKERMES USD 388.57M 227.88M Dec/2025
Amgen USD 9.13B 316M Dec/2025
AstraZeneca USD 8.14B 1.08B Sep/2025
Baxter International USD 1.97B 240M Dec/2025
Biogen USD 3.01B 854.3M Dec/2025
Bristol-Myers Squibb USD 10.21B 5.52B Dec/2025
Coherus Biosciences USD 88.88M 14.47M Dec/2025
Drreddys Laboratories INR 18.66B 9.65B Dec/2025
Eli Lilly USD 7.27B 2.52B Dec/2025
Gilead Sciences USD 7.33B 2.19B Sep/2025
GlaxoSmithKline GBP 3.3B 303M Sep/2025
Glaxosmithkline GBP 3.3B 303M Sep/2025
J&J USD 19.71B 1.48B Dec/2025
Medtronic USD 1.15B 135M Dec/2025
Merck USD 18.17B 10.16B Sep/2025
Neurocrine Biosciences USD 713M 372.8M Dec/2025
Novartis USD 9.56B 2.9B Sep/2025
Novartis USD 9.56B 2.9B Sep/2025
Novo Nordisk A/S DKK 18.44B 5.78B Jun/2025
Perrigo USD 432.1M 22.1M Sep/2025
Pfizer USD 1.34B 295M Sep/2025
Phibro Animal Health USD 55.49M 17.28M Dec/2025
Prestige Brands USD 62.37M 56.73M Dec/2025
Regeneron Pharmaceuticals USD 18.87B 16.36B Dec/2025
Roche Holding CHF 7.55B 579M Jun/2025
Sanofi EUR 7.66B 1.25B Dec/2025
Sanofi EUR 7.66B 1.25B Dec/2025
United Therapeutics USD 1.56B 217M Dec/2025
Zoetis USD 2.08B 649M Sep/2025